Neurological Presentation of Fabry's Disease in a 52 Year Old Man
JNNP 73:340-342, Mohanraj,R.,et al, 2002
Consent Issues in the Management of Cerebrovascular Diseases, A Position Paper of the American Academy of Neurology Ethics and Humanities Subcommittee
Neurol 53:9-11, , 1999
Cerebrovasc Dis Risk Factors:Neuroradiol Findings in Pts with Activated Protein C Resistance
Radiology 207:85-89, Provenzale,J.M.,et al, 1998
Cognitive Impairment & Mortality in a Cohort of Elderly People
BMJ 312:608-611, Gale,C.R.,et al, 1996
Reduced Response to Activated Protein C is Associated with Increased Risk for Cerebrovascular Disease
Ann Int Med 125:265-269, van der Bom,J.G.,et al, 1996
Prospective Study of Endogenous Tissue Plasminogen Activator and Risk of Stroke
Lancet 343:940-943, Ridker,P.M.,et al, 1994
Differential Diagnosis in Dementia, Principal Components Analysis of Clinical Data From a Population Survey
Arch Neurol 50:72-77, Jorm,A.F.,et al, 1993
Cerebral Artery Aneurysms in Children Infected with Human Immunodeficiency Virus
J Pediatr 121:927-930, Husson,R.N.,et al, 1992
Thrombolytic Therapy:Current Status (Second of Two Parts)
NEJM 318:1585-1595, Marder,V.J.&Sherry,S., 1988
Thrombolytic Therapy in Cerebrovascular Disease
Stroke 19:1174-1179, DelZoppo,G.J., 1988
Neurologic Manifestations of AIDS
Medicine 66:407-437, McArthur,J.C., 1987
Current Medical & Surgical Therapy for Cerebrovascular Disease
NEJM 317:1505-1516, Grotta,J.C., 1987